---
title: "华润医药旗下人凝血因子 IX 获内地药物临床试验批准通知书"
description: "华润医药公布，旗下华润博雅生物制药集团收到国家药品监督管理局颁发的人凝血因子 IX《药物临床试验批准通知书》。该产品用于凝血因子 IX 缺乏症 (血友病 B) 患者的出血治疗。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/276832369.md"
published_at: "2026-02-25T04:29:39.000Z"
---

# 华润医药旗下人凝血因子 IX 获内地药物临床试验批准通知书

> 华润医药公布，旗下华润博雅生物制药集团收到国家药品监督管理局颁发的人凝血因子 IX《药物临床试验批准通知书》。该产品用于凝血因子 IX 缺乏症 (血友病 B) 患者的出血治疗。

华润医药 (03320.HK) 公布，旗下华润博雅生物制药集团收到国家药品监督管理局颁发的人凝血因子 IX《药物临床试验批准通知书》。该产品用於凝血因子 IX 缺乏症 (血友病 B) 患者的出血治疗。

### Related Stocks

- [588130.CN - 华夏上证科创板生物医药ETF](https://longbridge.com/zh-CN/quote/588130.CN.md)
- [159892.CN - 华夏恒生生物科技ETF(QDII)](https://longbridge.com/zh-CN/quote/159892.CN.md)
- [159316.CN - 易方达恒生港股通创新药ETF](https://longbridge.com/zh-CN/quote/159316.CN.md)
- [300294.CN - 博雅生物](https://longbridge.com/zh-CN/quote/300294.CN.md)
- [520880.CN - 华宝恒生港股通创新药精选ETF](https://longbridge.com/zh-CN/quote/520880.CN.md)
- [159615.CN - 南方恒生生物科技ETF(QDII)](https://longbridge.com/zh-CN/quote/159615.CN.md)
- [510660.CN - 华夏医药ETF](https://longbridge.com/zh-CN/quote/510660.CN.md)
- [589720.CN - 国泰上证科创板创新药ETF](https://longbridge.com/zh-CN/quote/589720.CN.md)
- [159837.CN - 易方达中证生物科技主题ETF](https://longbridge.com/zh-CN/quote/159837.CN.md)
- [513120.CN - 广发中证香港创新药(QDII-ETF)](https://longbridge.com/zh-CN/quote/513120.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | [Link](https://longbridge.com/zh-CN/news/276822785.md) |
| China Medical System Gets China Acceptance for Atopic Dermatitis Drug | China Medical System Gets China Acceptance for Atopic Dermatitis Drug | [Link](https://longbridge.com/zh-CN/news/276718382.md) |
| CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab | CStone Pharmaceuticals has received UK approval for its lung cancer drug, sugemalimab, as a monotherapy for adult patien | [Link](https://longbridge.com/zh-CN/news/276549711.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-CN/news/276035104.md) |
| SinoMab Wins China IND Nod to Expand SM17 Into Inflammatory Bowel Disease | SinoMab Bioscience Ltd. has received approval from China's National Medical Products Administration for an investigation | [Link](https://longbridge.com/zh-CN/news/276765156.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。